• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Peripheral CEA-Specific T-Cell Changes Predict Colorectal Cancer Immunotherapy Outcomes

by
November 18, 2026
in Cancer, Health
Reading Time: 2 mins read
0
Peripheral CEA-Specific T-Cell Changes Predict Colorectal Cancer Immunotherapy Outcomes

Peripheral CEA-Specific T-Cell Changes Predict Colorectal Cancer Immunotherapy Outcomes

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An immune-monitoring assay measuring peripheral T-cell responses against carcinoembryonic antigen can predict clinical outcomes in colorectal cancer patients receiving anti-PD-1 therapy, according to a study published in Cancer Immunology, Immunotherapy. The investigators demonstrated that quantifying circulating CEA-specific CD8-positive T-cell activity provides valuable predictive insight into both objective tumor response and 12-month progression-free survival among patients with mismatch repair-deficient or microsatellite instability-high tumors.

Assessment of CEA-specific T-cell responses has long been considered a potentially clinically relevant approach for predicting treatment response and prognosis in colorectal cancer. However, the successful clinical translation of this monitoring strategy has previously been hindered by incomplete epitope mapping across the protein and a critical lack of standardized, broadly applicable immune-monitoring assays for clinical practice.

To overcome these clinical barriers, the authors systematically screened CD8-positive T-cell epitopes located within CEA. Their comprehensive discovery procedure integrated in silico computational prediction, co-culture experiments utilizing peptides and peripheral blood mononuclear cells, competitive binding assays, and immunizations performed in human leukocyte antigen-transgenic mouse models to confirm immune activation.

Through these multi-step screening efforts, the researchers validated 59 immunogenic CD8-positive T-cell epitopes restricted across 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes. These identified allotypes collectively cover more than 90 percent, 70 percent, and 90 percent of Northeast Asian populations, respectively, ensuring wide potential population applicability for the mapped targets.

Using the validated epitopes, the study established an interferon-gamma enzyme-linked immunospot assay to quantify circulating CEA-specific T-cell responses. The team then evaluated patients with dMMR and MSI-H colorectal cancer receiving anti-PD-1 therapy, assessing a derivation cohort of 80 patients alongside an independent test cohort of 21 patients, with objective response and 12-month progression-free survival serving as clinical endpoints.

In the derivation cohort, the post-treatment to pre-treatment CEA-specific T-cell fold change reliably predicted objective response with an area under the curve of 0.866 at a cut-off of 2.15, as well as 12-month progression-free survival with an area under the curve of 0.851 at a cut-off of 2.05. This cellular fold metric outperformed conventional markers, including KRAS and BRAF mutation status and early declines in serum CEA levels.

Based on these derivation findings, investigators predefined a unified fold cut-off of 2.1 for subsequent prospective validation in the independent cohort. In that 21-patient test group, the assay retained solid predictive efficacy, demonstrating area under the curve values of 0.809 for objective response and 0.824 for 12-month progression-free survival. The authors concluded that this peripheral blood readout serves as a clinically informative biomarker for stratifying response and progression-free survival following anti-PD-1 therapy in dMMR and MSI-H colorectal cancer.

Subject of Research: Peripheral CEA-specific T-cell responses as predictive biomarkers for anti-PD-1 therapy in colorectal cancer

Article Title: Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer

Article References: Zhu, S., Liu, W., Fu, H., Zhang, X., & Shen, C. (2026). Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04633-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04633-3

Keywords: CEA-specific T cells, anti-PD-1 therapy, colorectal cancer, dMMR, MSI-H, IFN-γ ELISpot, CD8+ T-cell epitopes, carcinoembryonic antigen, immune monitoring, progression-free survival, objective response, HLA allotypes, peripheral blood biomarker, immunotherapy stratification, KRAS mutation, BRAF mutation

News Source: Nathaniel Bowman. (November 18, 2026). Peripheral CEA-Specific T-Cell Changes Predict Colorectal Cancer Immunotherapy Outcomes. Scienmag.

Tags: Anti-PD-1 therapyBRAF mutationCarcinoembryonic AntigenCD8+ T-cell epitopesCEA-specific T cellsColorectal cancerdMMRHLA allotypesIFN-γ ELISpotimmune monitoringimmunotherapy stratificationKRAS mutationMSI-Hobjective responseperipheral blood biomarkerprogression-free survival
Share12Tweet7Share2ShareShareShare1

Related Posts

Retrograde Perfusion and Hypoventilation Intensify Brain Injury in Rat Extracorporeal Model

Retrograde Perfusion and Hypoventilation Intensify Brain Injury in Rat Extracorporeal Model

November 18, 2026
Multidimensional Review Evaluates Sustainability Pressures on China's Basic Medical Insurance Funds

Multidimensional Review Evaluates Sustainability Pressures on China’s Basic Medical Insurance Funds

November 18, 2026

Active Operating Room Involvement Correlates With Medical Student Interest in Surgical Careers

November 18, 2026

Interleukin-35 Drives Synovial Fibroblast Senescence to Suppress Rheumatoid Arthritis Progression

November 18, 2026

POPULAR NEWS

  • Novel Wheat Gene TaRLK-1B Identified as Key Leaf Rust Defense Regulator

    Novel Wheat Gene TaRLK-1B Identified as Key Leaf Rust Defense Regulator

    29 shares
    Share 12 Tweet 7
  • Herbal Decoction Drives Molecular Rearrangement Into Chiral Nanoribbons That Aid Lipophagy

    29 shares
    Share 12 Tweet 7
  • Semi-Supervised Deep Learning Framework Detects Smart Grid Cyber Attacks With High Accuracy

    29 shares
    Share 12 Tweet 7
  • County Physical Inactivity Strongly Links to Youth Obesity Rates Across Tennessee

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Retrograde Perfusion and Hypoventilation Intensify Brain Injury in Rat Extracorporeal Model

Multidimensional Review Evaluates Sustainability Pressures on China’s Basic Medical Insurance Funds

Active Operating Room Involvement Correlates With Medical Student Interest in Surgical Careers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.